ArticleRSC advances2023
Evaluation of a biosensor-based graphene oxide-DNA nanohybrid for lung cancer.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- An integrated and portable optoelectronic biosensing system for rapid post-extraction on-site quantification of Heterosigma akashiwo.Mikrochimica acta · 2026Article
- A comprehensive review of graphene-based biosensors: Fabrication, applications, characterization and future perspectives-A review.APL bioengineering · 2025Review
- Biomedical Applications of Metal-Organic Frameworks Revisited.Industrial & engineering chemistry research · 2025Review
- Artificial Intelligence-Powered Nanosensor Platforms for Non-Invasive Breathomic Diagnostics.Nanotechnology, science and applications · 2025Review
- Recent Developments in Aptamer-Based Sensors for Diagnostics.Sensors (Basel, Switzerland) · 2024Review
- The cutting-edge progress in bioprinting for biomedicine: principles, applications, and future perspectives.MedComm · 2024Review
- Review
- Interplay of graphene-DNA interactions: Unveiling sensing potential of graphene materials.Applied physics reviews · 2024Article
- A graphene oxide/polyaniline nanocomposite biosensor: synthesis, characterization, and electrochemical detection of bilirubin.RSC advances · 2023Article
- Severe plastic deformation: Nanostructured materials, metal-based and polymer-based nanocomposites: A review.Heliyon · 2023Review
- Optical properties of graphene oxide.Frontiers in chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is nowadays among the most prevalent diseases worldwide and features the highest mortality rate among various cancers, indicating that early diagnosis of the disease is of paramount importance. Given that the conventional methods of cancer detection are expensive and time-consuming, special attention has been paid to the provision of less expensive and faster techniques. In recent years, the dramatic advances in nanotechnology and the development of various nanomaterials have led to activities in this context. Recent studies indicate that the graphene oxide (GO) nanomaterial has high potential in the design of nano biosensors for lung cancer detection owing to its unique properties. In the current article, a nano biosensor based on a DNA-GO nanohybrid is introduced to detect deletion mutations causing lung cancer. In this method, mutations were detected using a FAM-labeled DNA probe with fluorescence spectrometry. GO was synthesized according to Hummers' method and examined and confirmed using Fourier Transform Infrared (FT-IR) Spectrometry and UV-vis spectrometry methods and Transmission Electron Microscopy (TEM) images.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.